Invivyd (IVVD) EBITDA Margin (2024 - 2025)
Invivyd (IVVD) reported EBITDA Margin of 64.33% for Q4 2025, up 6902.0% on a YoY basis from 0.92% in Q4 2024, and up 19.34% quarter-over-quarter from 79.76% in Q3 2025.
Invivyd (IVVD) EBITDA Margin (2024 - 2025) Analysis & Trends
Invivyd has reported EBITDA Margin for 2 years, with the latest figure at 64.33% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 6902.0% year-over-year to 64.33%; the trailing twelve-month figure through Dec 2025 stood at 98.31% (up 57107.0% YoY), and the FY2025 full-year result was 98.31%, up 57107.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 64.33%, up from 79.76% in the prior quarter.
- The five-year high for EBITDA Margin was 64.33% in Q4 2025, with the low at 2086.88% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -64.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64.33% |
| Sep 30, 2025 | -79.76% |
| Jun 30, 2025 | -124.61% |
| Mar 31, 2025 | -144.17% |
| Dec 31, 2024 | -133.36% |
| Sep 30, 2024 | -653.17% |
| Jun 30, 2024 | -2,086.88% |